Takeda To Share Rights To Anti-Obesity Drugs Of Amylin Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has agreed with U.S.-based Amylin Pharmaceuticals to co-develop its anti-obesity drugs and co-market them